In the late 1990 Wall road was abuzz about women's healthcare.

In the late 1990 Wall road was abuzz about women's healthcare. Biotechnology and pharmaceutical companies big and small were touting of recent origin diagnostic and therapeutic procedures for cervical and breast cancers, reproductive complications, menopausal oppressive flashes and other uniquely female medical puzzles In 1996 alone, six stocks in the field had initial public offerings (IPO), and by dint of the end of the decade magazines from Fortune to strange York were hyping the "enormous shooting potential" of this still-budding industry.

"There aren't true many of these companies

...